NewslettersCancer Stem Cell News Iovance’s AMTAGVI™ (lifileucel) Receives US FDA Accelerated Approval for Advanced Melanoma By Noshin Noorjahan - February 21, 2024 0 Iovance Biotherapeutics, Inc. announced that the US FDA has approved AMTAGVI™ suspension for intravenous infusion. [nan] Press Release